Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 2, 1999, Pages 145-150

  Zembower, David E ^a   Zhang, Heping ^a   Lineswala, Jayana P ^a   Kuffel, Mary J ^b   Aytes, Shelley A ^a   Ames, Matthew M ^b  

^a MediChem Research Inc   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; ED 110; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARBAZOLES; DNA TOPOISOMERASES, TYPE I; FEMALE; GLUCOSIDES; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033579985     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00710-0     Document Type: Article

References (20)

1. Liu, L.F. Annu. Rev. Biochem. 1989, 58, 351-375.
2. Schneider, E.; Hsiang, Y.-H.; Liu, L.F. Adv. Pharmacol. 1990, 21, 149-183.
3. Kojiri, K.; Kondo, H.; Yoshinari, T.; Arakawa, H.; Nakajima, S.; Satoh, F.; Kawamura, K.; Okura, A.; Suda, H.; Okanishi, M. J. Antibiot. 1991, 44, 723-728.
4. Tanaka, S.; Ohkubo, M.; Kojiri, K.; Suda, H. J. Antibiot. 1992, 45, 1797-1798.
5. Arakawa, H.; Iguchi, T.; Yoshinari, T.; Kojiri, K.; Suda, H.; Okura, A. Jpn. J. Cancer Res. 1993, 84, 574-581.
6. Arakawa, H.; Iguchi, T.; Morita, M.; Yoshinari, T.; Kojiri, K.; Suda, H.; Okura, A.; Nishimura, S. Cancer Res. 1995, 55, 1316-1320.
7. Ohkubo, M.; Kawamoto, H.; Ohno, T.; Nakano, M.; Morishima, H. Tetrahedron 1997, 53, 585-592.
8. Anizon, F.; Belin, L.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Severe, D.; Riou, J.-F.; Bailly, C.; Fabbro, D.; Meyer, T. J. Med. Chem. 1997, 40, 3456-3465.
9. Ohkubo, M.; Nishimura, T.; Jona, H.; Honma, T.; Morishima, H. Tetrahedron 1996, 52, 8099-8122.
10. Ohkubo, M.; Nishimura, T.; Jona, H.; Honma, T.; Ito, S.; Morishima, H. Tetrahedron 1997, 53, 5937-5950.
11. Batcho, A.D.; Leimgruber, W. Org. Synth. Coll. Vol. VII 1990, , 34-41.
12. Schmidt, E.K.G. Chem. Ber. 1974, 107, 2440-2452.
13. Pernak, J.; Jedraszczyk, J.; Krysinski, J. Pharmazie 1987, 42, 703-704.
14. 50 value was determined in triplicate, and are reported in Table 1 as the mean of three trials, having standard deviations ranging from 17% to 36% of the means. Prior to use, the activity of each stock of human Topo I (Topogen, Inc., Columbus, OH) was evaluated and normalized by titrating with pBR322 supercoiled plasmid DNA. One unit of enzyme activity was defined as the amount of enzyme which catalyzed the complete relaxation of 0.25 μg pBR322 DNA in 30 min under the above conditions at 37 °C. As another measure of control, it was verified that one unit of Topo I was completely inhibited by 100 μM camptothecin.
15. Bit, R.A.; Davis, P.A.; Elliot, L.H.; Harris, W.; Hill, C.H.; Keech, E.; Kumar, H.; Lawton, G.; Maw, A.; Nixon, J.S.; Vesey, D.R.; Wadsworth, J.; Wilkinson, S.E. J. Med. Chem. 1993, 36, 21-9.
16. Alley, M.C.; Scudiero, D.A.; Monks, A.; Hursey, M.L.; Czerwinski, M.J.; Fine, D.L.; Abbott, B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Cancer Res. 1988, 48, 589-601.
17. Yoshinari, T.; Yamada, A.; Uemura, D.; Nomura, K.; Arakawa, H.; Kojiri, K.; Yoshida, E.; Suda, H.; Okura, A. Cancer Res. 1993, 53, 490-494.
18. Madden, K.R.; Champoux, J.J. Cancer Res. 1992, 52, 525-532.
19. Sugimoto, Y.; Tsukahara, S.; Ohhara, T.; Isoe, T.; Tsuruo, T. Cancer Res. 1990, 50, 6925-6930.
20. Husain, I.; Mohler, J.L.; Seigler, H.F.; Besterman, J.M. Cancer Res. 1994, 54, 539-546.